> top > projects > sentences > docs > PubMed:19243381 > annotations
sentences Home  

PubMed:19243381 JSONTXT 7 Projects

Annnotations TAB TSV DIC JSON TextAE Lectin_function IAV-Glycan

Id Subject Object Predicate Lexical cue
TextSentencer_T1 0-65 Sentence denotes The hypereosinophilic syndromes: current concepts and treatments.
T1 0-65 Sentence denotes The hypereosinophilic syndromes: current concepts and treatments.
TextSentencer_T2 66-203 Sentence denotes The hypereosinophilic syndromes (HES) encompass a spectrum of diseases that have increased blood eosinophils and tissue damage in common.
T2 66-203 Sentence denotes The hypereosinophilic syndromes (HES) encompass a spectrum of diseases that have increased blood eosinophils and tissue damage in common.
TextSentencer_T3 204-302 Sentence denotes The clinical manifestations are protean and may involve any organ system, but especially the skin.
T3 204-302 Sentence denotes The clinical manifestations are protean and may involve any organ system, but especially the skin.
TextSentencer_T4 303-470 Sentence denotes Our understanding of these diseases has drastically changed over the past 15 years, along with new classifications that characterize patients with marked eosinophilia.
T4 303-470 Sentence denotes Our understanding of these diseases has drastically changed over the past 15 years, along with new classifications that characterize patients with marked eosinophilia.
TextSentencer_T5 471-595 Sentence denotes One HES variant, myeloproliferative, is actually chronic eosinophilic leukaemia with a unique genetic marker, FIP1L1-PDGFRA.
T5 471-595 Sentence denotes One HES variant, myeloproliferative, is actually chronic eosinophilic leukaemia with a unique genetic marker, FIP1L1-PDGFRA.
TextSentencer_T6 596-745 Sentence denotes Such patients are well-controlled by administration of the kinase inhibitor, imatinib, and remissions appear durable with continued imatinib therapy.
T6 596-745 Sentence denotes Such patients are well-controlled by administration of the kinase inhibitor, imatinib, and remissions appear durable with continued imatinib therapy.
TextSentencer_T7 746-862 Sentence denotes FIP1L1-PDGFRA is expressed in several cell lineages, thus explaining increases in neutrophils and mast cells in HES.
T7 746-862 Sentence denotes FIP1L1-PDGFRA is expressed in several cell lineages, thus explaining increases in neutrophils and mast cells in HES.
TextSentencer_T8 863-984 Sentence denotes The lymphocytic HES variant is associated with T-cell clones producing interleukin-5 (IL-5) and can evolve into lymphoma.
T8 863-984 Sentence denotes The lymphocytic HES variant is associated with T-cell clones producing interleukin-5 (IL-5) and can evolve into lymphoma.
TextSentencer_T9 985-1234 Sentence denotes While myeloproliferative and lymphocytic HES are well established and permit elimination of the term, idiopathic, to these varieties, most HES patients do not fall into these categories and are classified as complex (using the 2006 Workshop Report).
T9 985-1234 Sentence denotes While myeloproliferative and lymphocytic HES are well established and permit elimination of the term, idiopathic, to these varieties, most HES patients do not fall into these categories and are classified as complex (using the 2006 Workshop Report).
TextSentencer_T10 1235-1489 Sentence denotes A recent study showed that a monoclonal antibody to IL-5, mepolizumab, reduced glucocorticoid therapy in HES patients who did not possess the FIP1L1-PDGFRA mutation while controlling eosinophilia and preventing recurrence or progression of tissue damage.
T10 1235-1489 Sentence denotes A recent study showed that a monoclonal antibody to IL-5, mepolizumab, reduced glucocorticoid therapy in HES patients who did not possess the FIP1L1-PDGFRA mutation while controlling eosinophilia and preventing recurrence or progression of tissue damage.
TextSentencer_T11 1490-1581 Sentence denotes These advances augur well for continued progress in the understanding and treatment of HES.
T11 1490-1581 Sentence denotes These advances augur well for continued progress in the understanding and treatment of HES.